Stryker: The Sell-Off Creates A Better Entry Point, But Q2 Wasn't Perfect

Equity Lab 102 Followers Follow Summary Stryker rebounded in Q2 with 9% organic growth, restoring confidence after a weak Q1. Both the MedSurg & Neurotech and Orthopaedics segments sharply accelerated, indicating Q1 weakness was temporary. Guidance was modestly adjusted, but demand remains strong, and growth is broad-based across product lines. SYK's valuation has become more attractive post-selloff, supporting a maintained Buy rating despite lingering risks. JHVEPhoto/iStock Editorial via Getty Images Stryker’s ( SYK ) Q2 results were not perfect, but they gave me what I wanted to see: growth accelerated from the disappointing Q1 and both segments returned to healthy organic growth. Now, the stock sold off This article was written by Equity Lab 102 Followers Follow I am an equity investor with a strong focus on fundamental, bottom-up stock analysis combined with a structured macro framework. My investment approach centers on understanding business models in depth, assessing competitive positioning, and evaluating long-term value creation through disciplined valuation work. I focus on identifying companies with resilient cash flows, strong capital allocation, and durable competitive advantages. My sector focus is primarily on technology, healthcare, and utilities. I am particularly interested in how company fundamentals interact with broader macroeconomic developments. Alongside bottom-up research, I monitor key macro indicators such as interest rates, inflation, credit conditions, and policy developments to assess their impact on sector dynamics and valuation multiples I have gained experience in stock picking and portfolio management within institutional investment environments, contributing to idea generation and portfolio construction. I write on Seeking Alpha to publish data-driven investment theses grounded in fundamental analysis and valuation discipline. My objective is to provide clear, independent analysis with a long-term investment perspective. Analyst’s Disclosure: I/we have a beneficial long position in the shares of SYK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.